Latest News

Jyske Bank (CPSE:JYSK) has quietly delivered a strong run for shareholders, with the stock up about 7% over the past month and roughly 18% in the past 3 months. That outperformance raises a clear question: does the current price still make sense? See our latest analysis for Jyske Bank. Zooming out, that recent momentum sits on top of a powerful trend, with a year to date share price return above 60% and a five year total shareholder return near 300%. This suggests sentiment has steadily...

If you are wondering whether Bruker is quietly turning into a value opportunity, or if the recent share price is still too rich for the risks on the table, you are in the right place. After a tough stretch where the stock is still down 22.3% year to date and 20.6% over the last year, the recent 9.7% gain in the last 30 days and 0.7% move over the past week suggest that sentiment might be starting to shift. Recent headlines have focused on Bruker expanding its advanced scientific instruments...

In recent days, DoorDash and Uber filed a lawsuit against New York City challenging new rules that require food-delivery apps to display a default minimum 10% tip at checkout, arguing the law infringes on their constitutional rights and harms their business model. This legal fight highlights how changes to tipping rules in a key market could influence DoorDash’s cost structure, customer behavior, and long-term operating flexibility. We’ll now examine how this legal pushback against New...

If you are wondering whether Builders FirstSource is a bargain or a value trap at today’s price, you are not alone. That is exactly what we are going to unpack here. The stock has been choppy recently, down 2.6% over the last week and 26.3% year to date, even though the 3 year and 5 year returns remain a solid 59.5% and 157.0% respectively. Recent headlines have focused on the housing and renovation cycle, tighter financial conditions, and how material and labor dynamics could affect demand...

Levi & Korsinsky, LLP has filed a class action securities lawsuit against Baxter International, alleging that the company concealed serious safety defects in its Novum LVP infusion pumps and misled investors about product performance between February 23, 2022 and October 29, 2025. The complaint’s focus on reported malfunctions, injuries, and deaths linked to Novum LVP, alongside claims of inadequate remediation, raises material questions about Baxter’s product oversight, regulatory risk, and...

Plains All American Pipeline (PAA) has quietly outperformed the broader energy space over the past month, with shares edging higher as investors revisit midstream names for income, cash flow stability, and measured growth. See our latest analysis for Plains All American Pipeline. Zooming out, that steady climb to a share price of $17.87 sits on top of a roughly 5.5 percent 1 month share price return and a near 200 percent 5 year total shareholder return, which together signal that momentum in...

Wondering if EnerSys is still a smart buy after its big run, or if you would just be chasing momentum at this point? Let us walk through what the numbers actually say about its value. EnerSys has climbed to around $147.65, delivering 0.4% over the last week, 7.4% over the last month, and a hefty 60.3% year to date, with a 60.7% gain over the past year and 109.8% over three years, which hints that the market is steadily re-rating the stock. That surge has come as investors lean into energy...

In recent days, Green Thumb Industries drew heightened investor attention as trading volumes climbed to more than ten times their usual levels, even as the wider cannabis sector faced ongoing challenges. Analysts have responded with caution, pointing to valuation measures such as a high price-to-earnings ratio that may signal stretched expectations. With this surge in trading activity spotlighting Green Thumb Industries, we'll now examine how elevated investor interest interacts with its...

Wondering if Vestas Wind Systems is still worth buying after its huge run up, or if you have already missed the best of the upside? You are in the right place if you want a clear view on what the current price really implies. Vestas has quietly staged a big comeback, with the share price up 6.5% over the last week, 10.2% over the past month, and a striking 63.8% year to date, translating into an 80.1% gain over the last year despite still being down over 3 and 5 years. Part of this momentum...

Nebius Group (NBIS) has quietly become one of the market’s more polarising AI infrastructure plays, with shares sliding about 7% today but still up roughly 166% year to date. See our latest analysis for Nebius Group. That pullback comes after a roaring year, with Nebius’ year to date share price return of roughly 166% and a 12 month total shareholder return of about 177% showing that momentum is still strong, but now facing a healthy reality check on expectations. If Nebius has put AI...

BlackBerry (TSX:BB) has quietly put together a meaningful turnaround in its financials, with revenue and net income both climbing over the past year, even as the share price has lagged that improvement. See our latest analysis for BlackBerry. Yet the share price tells a more cautious story, with a roughly flat 90 day share price return of 5.97 percent and a far stronger 1 year total shareholder return of 28.51 percent, suggesting momentum is quietly rebuilding as investors reassess...

TOKYO BASELtd (TSE:3415) has posted its Q3 2026 numbers, with revenue at ¥5.6 billion and EPS of ¥2.92, while trailing twelve month revenue reached ¥22.6 billion and EPS came in at ¥24.82, underscoring a notable 77.7% year over year earnings uplift over the last year. The company has seen quarterly revenue move from ¥5.5 billion in Q3 2025 to ¥5.6 billion in Q3 2026, alongside EPS stepping down from ¥6.03 to ¥2.92 on a quarterly basis and stepping up from ¥13.72 to ¥24.82 on a trailing twelve...

Wondering if Equinor is a bargain or a value trap at today’s price? Here is a breakdown of what the recent share performance and fundamentals are really telling us before you make your next move. Despite being up an impressive 143.2% over the last 5 years, the stock is down 16.6% year to date and roughly flat over 1 year, which hints that the market is still undecided about its next leg. Recently, Equinor has stayed in the spotlight with headlines around its transition strategy in European...

Uber Technologies (UBER) just flipped the switch on commercial robotaxi rides in Dubai and Dallas, pairing autonomous launches with fresh retail delivery partnerships, a mix that could quietly reshape how investors think about its growth runway. See our latest analysis for Uber Technologies. All of this is landing just as sentiment around Uber has cooled in the near term, with a 30 day share price return of negative 10.65% and a 90 day share price return of negative 11.93%. Its 12 month total...

On December 11, 2025, Cogent Communications Holdings’ Vice President and Chief Financial Officer, Thaddeus Weed, sold 7,300 shares, adding to a year of insider stock sales with no recorded insider purchases. This steady pattern of executive selling over the past year, without offsetting insider buys, can influence how investors interpret leadership’s confidence and the company’s outlook. With the CFO’s latest share sale highlighting ongoing insider selling, we’ll examine how this activity...

Earlier in December 2025, UCB reported positive Phase 3 data at the American Epilepsy Society meeting showing adjunctive fenfluramine significantly reduced seizure frequency in children and adults with CDKL5 deficiency disorder, meeting its primary and key secondary endpoints over 14 weeks. This outcome strengthens fenfluramine’s clinical profile in a rare, severe epilepsy where no approved treatments currently exist, potentially broadening UCB’s neurology footprint if regulators eventually...

If you have ever looked at TransDigm Group and wondered whether the high share price is still justified, this breakdown is going to walk you through what the market might actually be paying for. The stock has cooled off a bit lately, with shares down around 2.0% over the last week and 3.6% over the past month, though longer term holders are still sitting on gains of 3.0% year to date and 8.4% over the last year, with a large 147.7% and 160.7% over 3 and 5 years respectively. Recent headlines...

Roth Capital’s latest move on Silvercorp Metals (TSX:SVM), keeping its Buy call while lifting its expectations, is the kind of steady vote of confidence that often nudges investors to take a closer look. See our latest analysis for Silvercorp Metals. The upbeat call comes as Silvercorp’s share price has climbed to $11.79, with a powerful 30 day share price return of 24.50% and 90 day share price return of 66.06%. The 1 year total shareholder return of 171.05% and 3 year total shareholder...

In recent days, IES Holdings reported strong fourth-quarter and full-year 2025 results, with revenue and earnings lifted by robust data center demand and the acquisition of Gulf Island Fabrication, while Director David Gendell and SVP Mary K. Newman sold shares in separate transactions. The combination of accelerating data center-related revenue and expanded capabilities from Gulf Island Fabrication marks a meaningful broadening of IES Holdings’ role in mission-critical infrastructure...

Wondering if Clear Secure is still a smart idea after its big run, or if the easy money has already been made? Here is a closer look at what the current price may be indicating about potential growth and risk. The stock has climbed 10.3% over the last week, 6.1% over the past month, and is up 43.8% year to date and 49.8% over the last year, putting it firmly on many investors' radar. Recent headlines have focused on Clear Secure expanding its airport footprint and broadening its identity...

Insmed (INSM) is joining the Nasdaq 100 on December 22, 2025, a move that can prompt additional demand from index tracking funds and draw a brighter spotlight on the company from institutional investors. See our latest analysis for Insmed. That Nasdaq 100 promotion caps a remarkable run, with Insmed’s share price returning 181.52 percent year to date and a three year total shareholder return of 944.67 percent, suggesting momentum is firmly building as investors reassess its growth runway. If...

Adaptive Biotechnologies (ADPT) just landed two non exclusive collaborations with Pfizer that lean heavily on its T cell receptor platform, a material win that could reshape both its revenue trajectory and strategic relevance. See our latest analysis for Adaptive Biotechnologies. The stock has been on a strong run, with a year to date share price return above 150 percent and a 1 year total shareholder return above 130 percent, helped by growing clonoSEQ adoption, insider selling headlines,...

DaVita (DVA) just handed investors a rough quarterly update, with earnings missing expectations as higher care and administrative costs, softer dialysis volumes, and lingering ransomware fallout weighed on results and sentiment. See our latest analysis for DaVita. Despite the latest miss and the earlier ransomware hit, DaVita’s 1 year total shareholder return of negative 20.28 percent and year to date share price return of negative 19.87 percent suggest momentum has clearly faded, even though...

Kimco Realty (KIM) has quietly moved higher this week, and that small uptick is a good excuse to revisit the stock’s bigger picture, from recent returns to how its portfolio is positioned. See our latest analysis for Kimco Realty. The latest 1 day and 7 day share price returns suggest sentiment is perking up a bit around Kimco Realty at 20.50 dollars, even though year to date share price performance and 1 year total shareholder return still point to a name working through a consolidation...